methylprednisolone has been researched along with moxifloxacin in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Agarwal, T; Jhanji, V; Sharma, N; Vajpayee, RB | 1 |
| Hu, Y; Shen, K; Shen, Y; Zhang, J | 1 |
| Liu, J; Long, X; Luo, H; Pan, X; Shen, F; Wang, S; Wu, J; Yao, L; Yuan, T | 1 |
| Tong, XC; Weng, SS; Wu, X; Xu, TM; Xue, F; Zhang, WH | 1 |
| Cao, Y; Xu, S; Zhou, M; Zhu, F | 1 |
| Chen, Q; Dai, Y; Gao, G; Han, W; Li, J; Li, L; Li, X; Liu, C; Quan, B; Wang, C; Yang, J; Zhang, G; Zhang, J; Zhang, Z; Zheng, W | 1 |
| Chen, F; Chen, Y; Fang, Q; Hu, S; Jiang, J; Liang, T; Lu, S; Sheng, J; Wei, N; Wu, L; Zheng, S; Zhou, J | 1 |
| Luo, S; Tian, M; Wang, L; Xia, W; Zeng, Y; Zha, Y; Zhang, K; Zhang, X | 1 |
1 review(s) available for methylprednisolone and moxifloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
13 other study(ies) available for methylprednisolone and moxifloxacin
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Presumed corneal stromal graft rejection after deep anterior lamellar keratoplasty in a patient with systemic lupus erythematosis.
Topics: Adolescent; Aza Compounds; Cornea; Corneal Edema; Corneal Stroma; Corneal Transplantation; Drug Administration Schedule; Drug Therapy, Combination; Eyeglasses; Female; Fluoroquinolones; Glucocorticoids; Graft Rejection; Humans; Injections, Intravenous; Keratoconus; Lupus Erythematosus, Systemic; Methylprednisolone; Moxifloxacin; Ophthalmic Solutions; Postoperative Complications; Postoperative Period; Prednisolone; Quinolines; Time Factors; Ultrasonography; Visual Acuity | 2010 |
Combination therapy with immune-modulators and moxifloxacin on fulminant macrolide-resistant Mycoplasma pneumoniae infection: A case report.
Topics: Anti-Bacterial Agents; Aza Compounds; Child; Disease Progression; Drug Therapy, Combination; Fluoroquinolones; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Male; Methylprednisolone; Moxifloxacin; Pneumonia, Mycoplasma; Pulse Therapy, Drug; Quinolines | 2013 |
Clinical characteristics from co-infection with avian influenza A H7N9 and Mycoplasma pneumoniae: a case report.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Coinfection; Female; Fluoroquinolones; Humans; Immunoglobulins; Influenza A Virus, H7N9 Subtype; Influenza, Human; Methylprednisolone; Moxifloxacin; Mycoplasma pneumoniae; Oseltamivir; Pneumonia, Mycoplasma | 2018 |
First human infection by a novel avian influenza A(H7N4) virus.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiviral Agents; China; Female; Genome, Viral; Humans; Influenza A virus; Influenza, Human; Methylprednisolone; Moxifloxacin; Oseltamivir; Radiography, Thoracic; Sequence Analysis, DNA; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China.
Topics: Anti-HIV Agents; Betacoronavirus; China; Clinical Laboratory Techniques; Coinfection; Coronavirus Infections; COVID-19; COVID-19 Testing; Diabetes Mellitus, Type 2; Drug Combinations; gamma-Globulins; HIV; HIV Infections; Humans; Lopinavir; Male; Methylprednisolone; Middle Aged; Moxifloxacin; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019.
Topics: Adolescent; Adult; Betacoronavirus; China; Clinical Laboratory Techniques; Contact Tracing; Coronavirus Infections; COVID-19; COVID-19 Testing; Female; Humans; Interferon alpha-2; Lopinavir; Male; Methylprednisolone; Middle Aged; Moxifloxacin; Oropharynx; Oxygen; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; RNA, Viral; SARS-CoV-2; Severity of Illness Index; T-Lymphocytes; Tomography, X-Ray Computed | 2020 |
First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder.
Topics: Antibodies, Viral; Antipsychotic Agents; Antiviral Agents; Betacoronavirus; Bipolar Disorder; Brain; Chest Pain; China; Clinical Laboratory Techniques; Cobicistat; Coronavirus Infections; COVID-19; COVID-19 Testing; Darunavir; Dyspnea; Fever; Glucocorticoids; Humans; Indoles; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Moxifloxacin; Olanzapine; Pandemics; Pharyngitis; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2 | 2020 |
The combined therapy of a traditional Chinese medicine formula and Western medicine for a critically ill case infected with COVID-19.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Combinations; Drugs, Chinese Herbal; Female; Humans; Indoles; Lopinavir; Medicine, Chinese Traditional; Methylprednisolone; Middle Aged; Moxifloxacin; Noninvasive Ventilation; Oxygen Inhalation Therapy; Pandemics; Pneumonia, Viral; Qi; Ritonavir; SARS-CoV-2 | 2020 |